IDEXX Laboratories (IDXX) 47th Annual Raymond James Institutional Investor Conference summary

Strategic overview and market opportunity

• Pursuing an innovation-driven strategy targeting a $45B+ global veterinary testing market, emphasizing diagnostics as foundational to practice health.

• Developing extensible platforms for point of care, software, and reference labs, leveraging installed base through menu extensions, vertical SaaS, and AI enablement.

• Commercial ecosystem expansion and customer partnerships drive awareness, education, and testing adoption, with international growth outpacing the U.S.

• Significant runway to expand premium instrument installed base over 3x globally, supported by investments in infrastructure and commercial teams.

• Long-term organic revenue growth potential projected at 10%+ with high return on invested capital.

Financial performance and growth drivers

• Achieved double-digit growth in both U.S. and international markets, with international recurring revenue growing from $0.7B in 2020 to $1.2B in 2025 at a 12% CAGR.

• Diagnostics revenue growth outpaces total practice and clinical revenue, driven by differentiated and integrated solutions.

• Pet longevity has increased by 22% since 2010, and increased pet adoption during the pandemic creates long-term tailwinds for diagnostics demand.

• Diagnostic spend rises with pet age; top third of practices use 1.5x more diagnostics than average.

• Long-term financial model targets 10%+ revenue growth, 50–100 bps operating margin expansion, and 15%+ EPS growth.

Innovation and product development

• Accelerated investment in innovation, with $1.2B planned over four years starting 2025 and cumulative R&D investment exceeding $2.4B.

• Focused on premium instruments, biomarkers, software, data, and AI enablement to address multi-billion-dollar disease states.

• Expanded vector-borne disease and parasitology testing menus, improving early detection and coverage.

• Renal and oncology diagnostics enhanced with early detection markers and expanded test panels.

• Point-of-care analyzers like Catalyst and inVue Dx offer menu extensibility and workflow integration, advancing cytology testing.